Related content

Response to “Impact of CYP3A4 Genotype on Voriconazole Exposure: New Insights Into the Contribution of CYP3A4*22 to Metabolism of Voriconazole”

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 103, Iss. 2, 2018-02 ,pp. : 187-187

John Wiley & Sons Inc

Access to resources Recommend Favorite

CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 65, Iss. 3, 2018-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

CORRIGENDUM: Identification and Characterization of a Defective CYP3A4 Genotype in a Kidney Transplant Patient With Severely Diminished Tacrolimus Clearance

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 5, 2014-11 ,pp. : 625-625

John Wiley & Sons Inc

Access to resources Recommend Favorite

High metabolic N‐oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 306-5251, Iss. 4, 2015-10 ,pp. : 782-784

John Wiley & Sons Inc

Access to resources Recommend Favorite

High metabolic N‐oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 80, Iss. 4, 2015-10 ,pp. : 782-784

John Wiley & Sons Inc

Access to resources Recommend Favorite